This article was originally published in The Tan Sheet
Japanese pharmaceutical firms terminate plans to form joint holding company that would have created country's third largest drug maker, Tanabe Seiyaku announces Dec. 3. "Differences regarding the most appropriate direction to be pursued post-merger, in addition to the differences existing in the companies' fundamental infrastructure, makes it unlikely for the companies to be able to take full advantage of their respective strengths and specialties or bring increased value to stockholders," Tanabe states. Under the plan, Taisho - Japan's top OTC producer - would have absorbed Tanabe's OTC business, while Tanabe would have integrated Taisho's Rx operations (1"The Tan Sheet" Sept. 24, In Brief)...
You may also be interested in...
Japanese firms' formation of joint holding company will create third largest drug maker in Japan with combined OTC sales of roughly $1.54 bil. Decision reflects "intensifying competition in the pharmaceutical industry" and "rapid changes in the business environment," firms say Sept. 17. Agreement comes on heels of GSK's July deal with Taisho to sell Nicoderm CQ in Japan (1"The Tan Sheet" July 2, In Brief). Companies will join forces April 2002, and by next October, Taisho - Japan's top OTC producer - will absorb Rx leader Tanabe's smaller OTC business; Tanabe will integrate Taisho's Rx operations
With the formal, virtual kick-off meeting set for 23 July, US FDA and sponsors are looking at a transformed landscape as they discuss what the next five years of user fees will look like.
Keeping Track: Approvals For Phexxi, Kynombi; New Claims For Lynparza, Alunbrig, Tecentriq; Intercept May Miss NASH User Fee Date
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.